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ABSTRACT 
Purpose  
Phenytoin is an effective anticonvulsant for focal epilepsy. Its use can be 
associated with long-term adverse effects including cerebellar ataxia. Whilst 
phenytoin is toxic to Purkinje cells in vitro; the clinical and radiological 
phenotype and mechanism of cerebellar degeneration in vivo remains 
unclear. We describe the prevalence, clinical and radiological characteristics 
of phenytoin-related ataxia. 
Methods 
Patients with epilepsy receiving treatment with phenytoin were recruited from 
the Epilepsy clinics at Royal Hallamshire Hospital, Sheffield, UK. Neurological 
examination was performed on all patients after recruitment. Patients were 
categorised into those with and without ataxia. We determined the severity of 
ataxia clinically (SARA score) and the pattern of cerebellar involvement by 
neuroimaging (MRI volumetry and MR spectroscopy).  
Results  
Forty-seven patients were recruited. Median duration of epilepsy was 24 
years, median duration of phenytoin treatment was 15 years and current 
median phenytoin daily dose was 325mg. Fifty-five percent of patients 
complained of poor balance. Clinical evidence of ataxia was seen in 40% 
patients. Gait, stance and heel-shin slide were the predominant features of 
cerebellar dysfunction. MRI demonstrated structural, volumetric and functional 
deficits of the cerebellum. Only one patient with ataxia had phenytoin levels 
above the normal range.  
Conclusions  
Cerebellar ataxia is present in 40% of patients with epilepsy and chronic 
exposure to phenytoin. Patients on long-term phenytoin have reduced 
cerebellar volume even if they have no clinical evidence of ataxia. Evidence of 
structural deficits on imaging suggests a predilection for vermian involvement. 
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1. INTRODUCTION 
1.1 Phenytoin (C15H12N202) is a hydantoin aromatic anticonvulsant. Its primary 
mode of action is the blockage of voltage-dependent neuronal sodium (Na+) 
channels(1). The sodium channel blockade increases the membrane 
threshold for depolarisation, ultimately lowering the neuronal cell susceptibility 
to epileptogenic stimuli.  
 
Phenytoin was first used as an anticonvulsant in 1938(2). This breakthrough 
discovery later established phenytoin as one of the most effective antiepileptic 
drugs (AEDs) available(3). Its use, however, is now in decline partly due to 
competition from new antiepileptic drugs, complex kinetic profile, multiple 
drug-interactions and long-term adverse effects that include abnormal bone 
mineral metabolism and potentially irreversible cerebellar ataxia. 
 
Patients with acute phenytoin intoxication may have drowsiness, nystagmus, 
dysarthria, tremor, ataxia and cognitive difficulties. Chronic phenytoin use is 
associated with cerebellar degeneration(4). Evidence for cause and effect is 
not always clear-cut; some reports suggest that cerebellar degeneration is 
secondary to seizure-mediated cell loss rather than a direct effect of 
phenytoin. However, phenytoin has been shown to be toxic to Purkinje cells in 
vitro(5-9). The prevalence of cerebellar damage in chronic phenytoin use and 
the clinical and radiological phenotype remain unclear.  
 
1.2 The aim of this study was to investigate the prevalence of ataxia in 
patients with epilepsy on long-term phenytoin and to determine the clinical 
and radiological characteristics of phenytoin-related ataxia. The study also 
aimed to determine any additional contributory factors to cerebellar 
degeneration. 
 
2. MATERIAL AND METHODS 
2.1 Patient selection and clinical assessments 
The study was approved by the regional ethics committee (Yorkshire & The 
Humber, UK). Patients with a clinical diagnosis of epilepsy taking long-term 
phenytoin treatment were identified from the Epilepsy outpatient clinics at the 
Royal Hallamshire Hospital, Sheffield, UK. Of 52 consecutive patients 
approached, (47/52) 90% agreed to take part. Written informed consent was 
obtained from all patients.  
 
‘Long-term phenytoin’ was defined as having been treated with phenytoin for 
more than 1 year. After recruitment, all patients underwent a full neurological 
examination focusing on clinical evidence of cerebellar ataxia and to exclude 
a peripheral neuropathy. Patients were categorised into 2 subgroups (PHT - 
patients with no clinical evidence of ataxia, and PHTA - patients with clinical 
evidence of ataxia). Only patients who were on phenytoin treatment at the 
time of study were included in the project. 
  
Detailed neurological history was obtained from the patients recruited and 
from their clinical records. This included type of epilepsy (focal, general or 
unclassified), duration of epilepsy, duration of phenytoin treatment and 
whether the patients had been on phenytoin from the time of the initial 
epilepsy diagnosis, current dose of phenytoin and any additional therapy with 
other antiepileptic agents. Age of onset, duration of symptoms of poor balance 
(ataxia) and requirement for mobility aids was documented in the subgroup of 
patients with PHTA.  
 
Cerebellar ataxia when present was classified as affecting gait, limb (lower +/- 
upper limb) or both and severity was assessed as mild (mobilising 
independently or with one walking aid), moderate (mobilising with 2 walking 
aids or walking frame) or severe (wheelchair-dependent). The severity 
assessment was adapted from previously published data(10). Objective 
measurement of the severity of ataxia was rated using the Scale for the 
Assessment and Rating of Ataxia (SARA)(11-12) (see supplementary 
material).  
 
2.2 Brain imaging 
Volumetric 3T MR imaging and single-voxel H1 MR spectroscopy of the 
cerebellum were undertaken in patients with clinical evidence of ataxia. The 
brain imaging protocols for structural, volumetric and spectroscopy studies 
have been previously reported(13-14). In the group of patients without ataxia, 
any existing volumetric 3T MR imaging that was done on participants, using 
the same imaging protocol, were included in the volumetric analysis.  
 
MR spectroscopy imaging outcome measures comprised of N-acetyl 
aspartate to creatine (NAA/Cr) area ratios of both the cerebellar vermis and 
hemisphere. MR volumetric imaging outcome measures comprised of 
cerebellar volume (expressed as a percentage of total intracranial volume, 
%CBV:TIV) and vermian volume (expressed as a percentage of total 
intracranial volume, %V:TIV). 
 
Patients included in the volumetric analysis were age- and gender- matched 
with healthy controls who had undertaken the same MR imaging protocol. The 
demographic details of the healthy controls who had undergone a thorough 
screening health questionnaire before inclusion have been reported 
previously(15).  
 
2.3 Blood collection and serological tests  
Blood samples were collected at recruitment. Tests included serum B12, 
folate and thyroid function. Immunological tests included total immunoglobulin 
levels, IgA and IgG anti-gliadin antibodies (AGA), anti-endomysial antibodies 
(EMA) and IgA anti-transglutaminase 2 (TG2) antibodies assayed at the 
Immunology Department, Northern General Hospital, Sheffield(14). Patient 
sera were also used for the detection of IgA and IgG to transglutaminase 6 
(TG6) by ELISA as previously described(16). Human Leukocyte Antigen 
(HLA) typing was performed at the National Blood Service, Sheffield, UK. 
Serum phenytoin levels were measured if there was clinical evidence of ataxia 
on examination. All patients were investigated for other causes of ataxia and 
no alternative aetiology was found. 
  
2.4 Statistical analysis 
Statistical analysis was performed using PRISM 6 software package 
(GraphPad Software Inc.). Demographic, clinical and imaging characteristics 
are presented as means with standard deviations (mean ± SD). The 
Independent-Samples Mann-Whitney U Test was used to determine any 
difference between mean cerebellar volume, expressed as a percentage of 
total intracranial volume (%CBV:TIV) and mean vermian volume, expressed 
as a percentage of total intracranial volume (%V:TIV) between patients and 
controls. The χ2 test was used for comparing the prevalence of anti-gliadin 
antibodies and anti-transglutaminase 6 antibodies in the study group with that 
of the healthy population; and between the subgroups. Results were 
considered statistically significant if p < 0.05. 
 
3. RESULTS 
3.1 Clinical presentation 
Forty-seven consecutive patients with known epilepsy and taking phenytoin 
long-term were recruited with mean age of 58 ± 13 years. There were 32 male 
and 15 female patients. Twenty-eight (60%) patients had focal epilepsy, 6/47 
(13%) had generalised epilepsy and in 13/47 (28%) patients the type of 
epilepsy was unclassified. Duration of epilepsy ranged from 2 to 67 years 
(median 24 years) and duration of phenytoin treatment ranged from one to 67 
years (median 15 years). Thirty (64%) patients had been taking phenytoin 
from the time of epilepsy diagnosis. The phenytoin total daily dose ranged 
from 100 to 600mg (median 325mg). Eighteen (38%) patients were taking 
phenytoin as monotherapy compared to 29/47 (62%) patients on combination 
antiepileptic therapy. Twenty four of the 29 (83%) patients on combination 
antiepileptic therapy were on one additional antiepileptic, 3/29 (10%) patients 
were on two additional antiepileptics and 2/29 (7%) patients were on 3 
additional antiepileptics. Twenty-six of the 47 (55%) patients complained of 
poor balance.  
 
Patients with clinical evidence of ataxia (PHTA) 
Ataxia (PHTA) was present in 19/47 (40%) patients. Three patients were 
taking phenytoin monotherapy; 15 patients were taking one additional anti-
epileptic therapy, and 1 patient was taking three additional anti-epileptic 
therapies. 
 
Age at onset of balance problems in this group of patients was 61 ± 9 years. 
None of the patients had clinical signs of peripheral neuropathy (i.e. distal 
sensory loss or depressed deep tendon reflexes). Duration of ataxia ranged 
from one to 16 years (median of 2 years). Pure gait ataxia was seen in 5/19 
(26%) patients with the majority having both gait and limb ataxia 14/19 (73%). 
Nystagmus was present in 9/19 (47%) patients.  
 
Fourteen of the nineteen (74%) patients had mild ataxia (mobilising 
independently or with one walking aid) compared to 5/19 (26%) patients with 
moderate (mobilising with 2 walking aids or walking frame) ataxia. No patients 
had severe ataxia. The severity of ataxia using the SARA scale revealed a 
mean total SARA score of 8 ± 5 (range 4 to 17). There was a correlation seen 
between duration of ataxia and total SARA score (p 0.0122). 
 
Table 1 demonstrates the frequency of involvement for each of the eight key 
SARA elements. The gait (100%), stance (95%) and heel-shin slide (79%) 
were the predominant SARA elements affected. 
 
Table 1 Scale for the assessment and rating of ataxia (SARA) in patients with                                      
phenytoin-related ataxia 
SARA elements Phenytoin-related ataxia  
Gait 19/19 (100%) 
Stance 18/19 (95%) 
Sitting 2/19 (11%) 
Speech disturbance 1/19 (5%) 
Finger chase 7/19 (37%) 
Nose-finger test 8/19 (42%) 
Fast alternating hand movements 8/19 (42%) 
Heel-shin slide 15/19 (79%) 
 
3.2 Brain imaging 
MR Spectroscopy data analysis was based on 10 optimal scans done on 
patients with PHTA. The decision to exclude suboptimal MR spectroscopy 
data was based on previous published criteria(17). Abnormal NAA/Cr area 
ratio (vermis NAA/Cr area ratio < 0.95 and/or hemisphere NAA/Cr < 1.00)(18) 
was recorded in 8/10 (80%) patients with PHTA. Predominantly vermian 
abnormalities were present in 5/10 (50%) patients with PHTA. The 
hemisphere was solely affected in 3/10 (30%) patients with PHTA. There was 
no significant difference between the prevalence of abnormal spectroscopy in 
the vermis vs. the cerebellar hemispheres. 
 
3T MRI was available in 30 of the 47 patients. MRI was contraindicated in 5 
patients and there were no available MRI data in 12 patients. The clinical 
reporting of cerebellar atrophy was undertaken by a neuroradiologist (NH) 
with expertise in cerebellar imaging.  Cerebellar atrophy was reported in 13/30 
(43%) patients with epilepsy taking phenytoin that comprised of 7/17 (41%) 
patients without ataxia and 6/13 (46%) patients with ataxia. Vermian atrophy 
was present in 12/13 (92%) patients and hemispheric atrophy in 5/13 (38%) 
patients.  
 
MRI data that did not contain appropriate T1 volume sequences or follow the 
appropriate imaging protocol were excluded from volumetric analysis. 
Volumetric image analysis matched for age and gender with healthy controls 
was possible in 17 patients taking phenytoin. The analysis was thus based on 
8 patients without ataxia (PHT) and 9 patients with ataxia (PHTA). Results are 
displayed as a whole group (PHT and PHTA) vs. age and gender matched 
healthy controls, subgroup PHT or PHTA vs. age and gender matched healthy 
controls and PHT vs. PHTA. 
 
Cerebellar volume was significantly smaller (8.30 ± 1.05) in the whole study 
group (PHT and PHTA) when compared with healthy controls (9.36 ± 0.88); 
CI 95% 7.75 to 8.84, p 0.0015. There was correlation between duration of 
phenytoin and cerebellar volume (p 0.0247). 
 
Cerebellar volume was significantly smaller in the subgroup PHT (8.88 ± 0.82) 
vs. healthy controls (9.71 ± 0.65); CI 95% 8.20 to 9.57, p 0.0188. Cerebellar 
volume was also significantly smaller in the subgroup PHTA (7.77 ± 0.99) 
compared to healthy controls (9.04 ± 0.97); CI 95% 7.02 to 8.53, p 0.0174. 
 
Cerebellar volume was significantly smaller in the subgroup PHTA (7.77 ± 
0.99) compared to the subgroup PHT (8.88 ± 0.82); CI 95% 7.02 to 8.53, p 
0.0360. 
 
Vermian volume was not significantly different when comparing the whole 
group and the subgroups with healthy controls. There was no correlation 
demonstrated between the severity of ataxia with cerebellar vermian or 
hemispheric NAA/Cr area ratio or with cerebellar volume. 
 
3.3 Serological testing for gluten-related antibodies 
Normal serum immunoglobulins were seen in 24/47 (51%) patients on 
phenytoin. Six of the 47 (13%) patients had low IgA levels including one 
patient with severe IgA deficiency. 
 
Circulating anti-gliadin antibodies and / or TG2 were detected in 5/47 (11%) 
patients. None of the patients had circulating EMA. There was no difference in 
the prevalence of circulating anti-gliadin antibodies between the ataxic and 
non-ataxic patients taking phenytoin, and when compared to the healthy 
population.  
 
Antibodies to TG6 were detected in 4/47 (9%) patients taking phenytoin. A 
similar proportion of healthy controls have been reported to have circulating 
anti-TG6 antibodies(19). There was no significant difference between the 
subgroups of patients. 
 
3.4 HLA genotyping for DQ2 / DQ8 
Nineteen of the 47 (40%) patients in the whole study group had HLA typing for 
DQ2 or DQ8. This was similar to the healthy population (30%, Dewar, 2004). 
There was no significant difference between the subgroups, using the χ2 test. 
 
3.5 Serum phenytoin levels 
Phenytoin levels in the subgroup of patients with PHTA ranged from 2.0 g/L to 
65.8 g/L (median 13.2 g/L).  Only one of the nineteen patients with ataxia had 
phenytoin levels in the potentially intoxicating range (65.8 g/L) indicating that 
the ataxia in this group of patients was not a result of current phenytoin 
intoxication.  
 
4. DISCUSSION 
To our knowledge this is the first study detailing the clinical and radiological 
characteristics of cerebellar ataxia in patients with epilepsy and chronic 
exposure to phenytoin.  Whilst 55% of patients complained of poor balance, 
clinical evidence of ataxia was present in 40%. Patients with phenytoin-related 
ataxia appear to predominantly have gait and limb ataxia of mild severity 
(mobilising independently or with one walking aid). Only 1 patient had 
phenytoin levels above the normal range indicating that the ataxia in this 
group of patients was not a result of acute phenytoin intoxication. Previous 
studies have focused on patients with symptoms of phenytoin intoxication that 
manifest as nystagmus, tremor and ataxic syndrome, some of which are 
reversible on treatment adjustment and/or cessation.  
 
The mean total SARA score in patients with phenytoin-related ataxia was 8 ± 
5 implying mild ataxia. There was correlation between duration of ataxia and 
total SARA score (p 0.0122). The gait (100%), stance (95%) and heel-shin 
slide (79%) of the SARA elements were predominantly affected. No 
correlation was found between duration of epilepsy or duration of phenytoin 
treatment with the total SARA score. Clinically this study suggests that the 
type of ataxia seen in patients on long-term phenytoin is predominantly 
vermian. 
 
None of the patients with phenytoin-related ataxia had clinical signs of 
peripheral neuropathy. This clinical exclusion in our study supports that the 
cerebellum is primarily involved in patients with epilepsy and chronic exposure 
to phenytoin. Although previous studies have shown that peripheral 
neuropathy can be associated with phenytoin, no link was found between 
phenytoin levels or the duration of phenytoin with the development of clinical 
neuropathy (20). 
 
Structural evaluation with 3T MRI revealed variable degrees of cerebellar 
atrophy consistent with published literature(21). The presence or not of 
cerebellar atrophy did not correlate with clinical evidence of ataxia, though 
there was a correlation between duration of treatment with cerebellar volume 
loss. Patients with phenytoin-related ataxia (as assessed clinically) had 
significantly smaller cerebellar volumes compared to patients on phenytoin 
without ataxia. This suggests that cerebellar atrophy is not always associated 
with clinical evidence of cerebellar dysfunction and that there may be a 
threshold beyond which atrophy will be accompanied by cerebellar signs. 
 
Previous studies have not compared imaging with clinical findings in patients 
prescribed phenytoin but correlation between cerebellar atrophy and duration 
of epilepsy has been previously shown(22). This may reflect a correlation 
between duration of epilepsy and exposure to antiepileptic drugs and 
therefore it is impossible to tease out any direct effect of the epilepsy alone. 
MR spectroscopy appears potentially more sensitive than volumetry in 
detecting underlying cerebellar dysfunction prior to demonstration of 
cerebellar structural abnormalities(23). MR spectroscopy reflects underlying 
tissue biochemistry at the time of the scan as well as underlying structural 
changes such as reduction in the number of neurons; whereas volumetry 
represents accumulated cellular loss over the life of the patient. 
 
Prevalence of gluten-related serology was no different to that in healthy 
controls. The above findings concur with a previous study on gluten-related 
antibodies in patients with epilepsy that included patients taking phenytoin 
and the healthy population(24).  Results for HLA DQ2/DQ8 (often associated 
with a tendency to autoimmunity) were not significant. We therefore, did not 
identify any potential additional factors likely to be contributing to the 
development of ataxia in this group of patients. 
 
This study is limited by the relatively small sample size.  Details of historical 
phenytoin levels or previous episodes of toxicity were not readily accessible. 
We did not have sufficient information about previous dosing to work out a life 
time total phenytoin dose or mean phenytoin blood level. We have also not 
accounted for effects of combinations of phenytoin with other antiepileptic 
drugs, whether seizure control had any influence on volumetric loss and 
whether either factor was associated with ataxia. A comparison with a group 
of patients with epilepsy on different anticonvulsant(s) may be a future 
direction. 
 
5. CONCLUSIONS 
This study shows that the prevalence of ataxia in patients with epilepsy and 
chronic exposure to phenytoin is 40% and that patients on long-term 
phenytoin have reduced cerebellar volume even if they have no clinical 
evidence of ataxia. The absence of additional contributory factors to the ataxia 
suggests that this is a direct toxic effect of phenytoin. 
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Scale for the assessment and rating of ataxia (SARA) 
 
1) Gait 
Proband is asked (1) to walk at a safe distance parallel to 
a wall including a half-turn (turn around to face the 
opposite direction of gait) and (2) to walk in tandem 
(heels to toes) without support.  
 
 
 
0 Normal, no difficulties in walking, turning and  
       walking tandem (up to one misstep allowed) 
   1     Slight difficulties, only visible when walking 10  
          consecutive steps in tandem 
   2     Clearly abnormal, tandem walking >10 steps not      
          possible 
   3     Considerable staggering, difficulties in half-turn, but  
          without support 
   4    Marked staggering, intermittent support of the wall  
          required 
   5     Severe staggering, permanent support of one stick or  
          light support by one arm required 
6 Walking > 10 m only with strong support (two  
        special sticks or stroller or accompanying person)  
7 Walking < 10 m only with strong support (two  
        special sticks or stroller or accompanying person)  
   8     Unable to walk, even supported 
2) Stance 
Proband is asked to stand (1) in natural position, (2) with 
feet together in parallel (big toes touching each other) and 
(3) in tandem (both feet on one line, no space between 
heel and toe). Proband does not wear shoes, eyes are 
open. For each condition, three trials are allowed. Best 
trial is rated. 
 
   0     Normal, able to stand in tandem for > 10 s 
   1     Able to stand with feet together without sway, but  
          not in tandem for > 10s 
   2     Able to stand with feet together for > 10 s, but only  
         with sway 
   3     Able to stand for > 10 s without support in natural  
         position, but not with feet together 
   4     Able to stand for >10 s in natural position only with  
          intermittent support 
   5     Able to stand >10 s in natural position only with  
         constant support of one arm  
   6     Unable to stand for >10 s even with constant support  
          of one arm 
 
  Score    Score  
3) Sitting 
Proband is asked to sit on an examination bed without 
support of feet, eyes open and arms outstretched to the 
front. 
 
   0     Normal, no difficulties sitting >10 sec 
   1     Slight difficulties, intermittent sway 
2 Constant sway, but able to sit > 10 s without support 
   3     Able to sit for > 10 s only with intermittent support 
   4     Unable to sit for >10 s without continuous support 
 
4) Speech disturbance 
Speech is assessed during normal conversation. 
 
 
 
   0     Normal 
   1     Suggestion of speech disturbance 
   2     Impaired speech, but easy to understand 
   3     Occasional words difficult to understand 
   4     Many words difficult to understand 
   5     Only single words understandable 
   6     Speech unintelligible / anarthria 
  Score     Score  
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5) Finger chase  
Rated separately for each side 
Proband sits comfortably. If necessary, support of feet 
and trunk is allowed. Examiner sits in front of proband 
and performs 5 consecutive sudden and fast pointing 
movements in unpredictable directions in a frontal plane, 
at about 50 % of proband´s reach. Movements have an 
amplitude of 30 cm and a frequency of 1 movement 
every 2 s. Proband is asked to follow the movements 
with his index finger, as fast and precisely as possible. 
Average performance of last 3 movements is rated.  
 
   0     No dysmetria  
   1     Dysmetria, under/ overshooting target <5 cm 
   2     Dysmetria, under/ overshooting target < 15 cm  
   3     Dysmetria, under/ overshooting target > 15 cm 
   4     Unable to perform 5 pointing movements 
 
6) Nose-finger test  
Rated separately for each side 
Proband sits comfortably. If necessary, support of feet 
and trunk is allowed. Proband is asked to point repeatedly 
with his index finger from his nose to examiner’s finger 
which is in front of the proband at about 90 % of 
proband’s reach. Movements are performed at moderate 
speed. Average performance of movements is rated 
according to the amplitude of the kinetic tremor.  
 
 
 
   0     No tremor  
   1     Tremor with an amplitude < 2 cm 
   2     Tremor with an amplitude < 5 cm  
   3     Tremor with an amplitude > 5 cm  
   4     Unable to perform 5 pointing movements  
Score Right Left Score Right Left 
mean of both sides (R+L)/2  mean of both sides (R+L)/2  
7) Fast alternating hand movements  
Rated separately for each side  
Proband sits comfortably. If necessary, support of feet 
and trunk is allowed. Proband is asked to perform 10 
cycles of repetitive alternation of pro- and supinations of 
the hand on his/her thigh as fast and as precise as 
possible. Movement is demonstrated by examiner at a 
speed of approx. 10 cycles within 7 s. Exact times for 
movement execution have to be taken. 
 
   0     Normal, no irregularities (performs <10s) 
   1     Slightly irregular (performs <10s) 
   2     Clearly irregular, single movements difficult  
          to distinguish or relevant interruptions, but   
          performs <10s 
   3    Very irregular, single movements difficult  
          to distinguish or relevant interruptions,  
          performs >10s 
   4     Unable to complete 10 cycles 
  
8) Heel-shin slide  
Rated separately for each side 
Proband lies on examination bed, without sight of his 
legs. Proband is asked to lift one leg, point with the heel 
to the opposite knee, slide down along the shin to the 
ankle, and lay the leg back on the examination bed. The 
task is performed 3 times. Slide-down movements should 
be performed within 1 s. If proband slides down without 
contact to shin in all three trials, rate 4.  
 
   0     Normal 
   1     Slightly abnormal, contact to shin maintained  
2 Clearly abnormal, goes off shin up to 3 times   
       during 3 cycles 
3 Severely abnormal, goes off shin 4 or more times  
       during 3 cycles 
   4     Unable to perform the task 
 
      Score Right Left   Score Right Left 
  mean of both sides (R+L)/2    mean of both sides (R+L) / 2  
Patient ID Gender Age at 
study, y 
Subgroup Epilepsy type  Treated on 
additional AED  
6* female 67 PHTA unclassified PMD 
7 male 67 PHTA generalised LTC 
10* male 57 PHT focal ZNS 
11 male 54 PHT focal CBZ 
12 female 59 PHT focal LTC, PGL, PHB 
13* female 63 PHT unclassified - 
14* female 77 PHTA general PHB 
15 male 49 PHT focal PGL 
16 male 54 PHT focal PGL, OXC 
17* male 65 PHT generalised - 
19 male 32 PHT focal LTG 
22 male 74 PHTA focal LTC 
26 female 42 PHT unclassified - 
41 male 54 PHTA unclassified LTC 
42* male 77 PHT unclassified - 
48* male 53 PHTA generalised - 
60* female 72 PHTA unclassified VPA 
65 male 73 PHTA focal - 
66* female 69 PHT focal CBZ, LTC 
68* female 74 PHTA focal LTG 
71* male 32 PHT focal VPA 
73* male 71 PHTA generalised VPA 
74* female 70 PHTA focal PGL 
75* female 63 PHTA generalised PHB 
76* female 57 PHTA unclassified VPA 
79 male 39 PHT focal - 
80* male 65 PHTA focal PGL 
81* male 62 PHT unclassified - 
82* male 39 PHT unclassified - 
83 male 46 PHT focal LTG 
84 male 43 PHT unclassified LTC, VPA 
87* male 48 PHT unclassified - 
88* male 67 PHT focal PHB 
93 male 40 PHT focal LTC 
96* female 66 PHT focal - 
97* male 63 PHTA focal - 
98 female 61 PHTA focal CBZ 
111* male 88 PHT focal - 
113 male 43 PHT focal - 
115* male 52 PHT unclassified - 
124 male 57 PHT focal LTC 
126* female 60 PHTA focal CBZ 
129* male 49 PHT focal - 
130* male 55 PHTA focal CBZ, LTC, ZNS 
131* male 36 PHT focal - 
141* female 60 PHT unclassified - 
144* male 64 PHTA focal PHB 
* = on phenytoin from time of initial diagnosis of epilepsy, y = years, PHT = no ataxia, PHTA = with ataxia,  
CBZ = carbamazepine, LTC = levetiracetam, LTG = lamotrigine, PHB = phenobarbital, PGL = pregabalin, PMD = primidone,  
OXC = oxcarbazepine, VPA = sodium valproate, ZNS = zonisamide 
 
Demographics of patients with epilepsy on long-term phenytoin 
 
Patient ID Phenytoin 
level (g/L) 
Severity of 
ataxia 
Gait Stance Sitting Speech 
disturbance 
Finger 
chase 
Nose-
finger 
test 
Fast alternating 
hand movements 
Heel-
shin 
slde 
Total 
SARA 
score 
Cerebellar 
volume 
(%CBV:TIV) 
6 26.8 mild 2 0 0 0 0 0 1 1 4 9.38 
7 2.0 mild 2 3 0 0 0 0 0 0 5 n/a 
14 28.8 mild 3 3 0 0 0 0 0 0 6 n/a 
22 65.8 moderate 5 4 1 0 1 1 1 2 15 n/a 
41 9.0 moderate 5 4 0 1 0 0 0 1 11 8.61 
48 21.3 mild 2 1 0 0 0.5 0.5 0 1 5 6.96 
60 9.5 moderate 7 5 0 0 0 0 1 4 17 n/a 
65 12.2 mild 2 3 0 0 0 0 0 1 6 7.77 
68 14.6 mild 2 2 0 0 0 0 0 0 4 n/a 
73 17.6 mild 3 3 0 0 1 1 1 2 11 8.12 
74 14.6 mild 3 2 0 0 0 0 0 0 5 n/a 
75 10.1 mild 1 2 0 0 0 1 0 1 5 6.19 
76 1.8 mild 2 2 0 0 0.5 0.5 0.5 0.5 6 7.73 
80 7.9 moderate 5 5 1 0 1 1 1 3 17 n/a 
97 28.1 mild 2 2 0 0 2 2 1 1 10 8.36 
98 n/a mild 3 1 0 0 0 0 0 1 5 6.84 
126 7.9 mild 2 2 0 0 0 0 0 0.5 4.5 n/a 
130 14.2 mild 2 2 0 0 0 0 0 1 5 n/a 
144 11.8 moderate 5 5 0 0 1.5 1.5 0.5 3 16.5 n/a 
clinical characteristics (severity of ataxia, SARA elements subscores, total SARA score) of 19 patients with phenytoin-related ataxia (PHTA), SARA = Scale for the assessment and rating of ataxia,  
only volumetric imaging data (cerebellar volume) of patients that were age- and gender- matched with healthy controls displayed, cerebellar volume is expressed as a percentage of total intracranial volume (%CBV:TIV)  
 
Clinical characteristics and volumetric imaging data in patients with phenytoin-related ataxia  
MRI TI midline sagittal and axial T2-weighted images in a healthy patient (a,c) 
and in a patient with cerebellar atrophy (b,d) 
b a 
c d 
